Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | HSD17B3 | P37058 | 7/20 | 0.43 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16016907 | 0.90 | THRA (0.48) | THRATHRBHSD17B3HCAR3ALDH1A1 | |
| SCHEMBL1611950 | 0.89 | THRA (0.48) | THRATHRBHSD17B3HCAR3ALDH1A1 | |
| SCHEMBL16016735 | 0.82 | THRA (0.41) | THRATHRBHSD17B3HCAR3GAA | |
| SCHEMBL1612238 | 0.79 | THRA (0.51) | THRATHRBHSD17B3HCAR3ALDH1A1 | |
| SCHEMBL3032106 | 0.79 | KCNH2 (0.40) | ALDH1A1 | |
| SCHEMBL2954189 | 0.76 | MAPK1 (0.57) | POLB | |
| SCHEMBL11765445 | 0.76 | LMNA (0.57) | THRATHRBHSD17B3HCAR3ALDH1A1 | |
| SCHEMBL11444533 | 0.75 | TSHR (0.60) | THRATHRBHSD17B3HCAR3ALDH1A1 | |
| SCHEMBL28029786 | 0.74 | HCAR3 (0.53) | THRATHRBHSD17B3HCAR3GAA | |
| SCHEMBL6834169 | 0.73 | GPR35 (0.50) | ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2311792-B1 | Friedel-Crafts acylation for synthesis of aryl and heteroaryl-(3-ethyl-4-nitro-phenyl)-methanones | ROCHE DIAGNOSTICS GMBH (DE) | 2013-05-15 | — | — | EP | claimed |
| EP-2311792-A1 | Friedel-Crafts acylation for synthesis of aryl and heteroaryl-(3-ethyl-4-nitro-phenyl)-methanones | Roche Diagnostics GmbH (DE) | 2011-04-20 | — | — | EP | claimed |
| US-20110087013-A1 | Friedel-Crafts acylation for the synthesis of aryl- and heteroaryl-(3-ethyl-4-nitrophenyl)-methanones | ROCHE NIMBLEGEN, INC. | 2011-04-14 | — | — | US | claimed |
| EP-2311792-B1 | Friedel-Crafts acylation for synthesis of aryl and heteroaryl-(3-ethyl-4-nitro-phenyl)-methanones | ROCHE DIAGNOSTICS GMBH (DE) | 2013-05-15 | — | — | EP | disclosed |
| EP-2311792-A1 | Friedel-Crafts acylation for synthesis of aryl and heteroaryl-(3-ethyl-4-nitro-phenyl)-methanones | Roche Diagnostics GmbH (DE) | 2011-04-20 | — | — | EP | disclosed |
| EP-2311792-A1 | Friedel-Crafts acylation for synthesis of aryl and heteroaryl-(3-ethyl-4-nitro-phenyl)-methanones | Roche Diagnostics GmbH (DE) | 2011-04-20 | — | — | EP | disclosed |
| US-20110087013-A1 | Friedel-Crafts acylation for the synthesis of aryl- and heteroaryl-(3-ethyl-4-nitrophenyl)-methanones | ROCHE NIMBLEGEN, INC. | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110087013-A1 | Friedel-Crafts acylation for the synthesis of aryl- and heteroaryl-(3-ethyl-4-nitrophenyl)-methanones | CYP2B6, HNF4A, AHR | THRA 1841/4885THRB 2017/4885HSD17B3 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.